MedTrace Logo

Bleeding Disorder of Unknown Cause in the Netherlands

NCT07454161 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-04-27

No results posted yet for this study

Summary

The purpose of the Bleeding Disorder of Unknown Cause in the Netherlands study (BDUC-iN) is to learn more about unexplained bleeding in individuals with a bleeding disorder of unknown cause (BDUC). The study aims to better understand why these individuals have increased bleeding and how it affects their health and daily life.

The main questions of this study are:

1. What are the mechanisms underlying the bleeding tendency in BDUC?
2. How do bleeding symptoms affect patients' daily functioning and overall health-related quality of life?
3. How is care delivered to individuals with BDUC, and how can this be improved?

Participants with increased bleeding tendency who remain undiagnosed after standard coagulation testing and are consequently classified as having BDUC will be enrolled across the Hemophilia treatment centers in the Netherlands. Participants will undergo blood sampling for advanced hemostasis testing and genetic analysis. In addition, participants will complete validated questionnaires to assess bleeding symptoms and health-related quality of life. Participants will be followed longitudinally to evaluate how bleeding symptoms affect daily activities, medical procedures, and overall health-related quality of life.

Conditions

  • Hemorrhagic Disorders
  • Bleeding Disorder of Unknown Cause

Sponsors & Collaborators

  • Sanquin Research & Blood Bank Divisions

    collaborator OTHER

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • F.C.J.I. Heubel-Moenen, Dr. · Maastricht University Medical Center

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2039-03-01
Completion
2039-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07454161 on ClinicalTrials.gov